Sera Prognostics Inc是一家女性健康诊断公司,专注于利用其蛋白质组学和生物信息学平台发现、开发和商业化具有临床影响的生物标志物测试,最初专注于改善妊娠后果。该公司建立了一个蛋白质组学和生物信息学平台,以描述妊娠生物学特征,并发现和验证血液中发现的关键蛋白质生物标记物,这些标记物是妊娠期间发生的动态变化的准确预测因子。该公司的商业产品,早产儿测试,是一种基于血液的生物标志物测试,可以准确预测早产的风险,也称为早产。预胎试验是一种非侵入性血液试验,在妊娠第19周或第20周期间,对携带单个胎儿的孕妇进行。其生物标志物妊娠途径包括先兆子痫、分子生育时间、妊娠糖尿病(GDM)、胎儿生长受限、死产和产后抑郁症。
名称 | 标题 | 任期 | 年龄 |
|---|---|---|---|
| Kim Puloma Kamdar | Independent Chairman | 2023 | 59 |
| Zhenya Lindgardt | President, CEO & Director | 2023 | 52 |
| Gregory C. Critchfield | Executive Director | 2023 | 73 |
| Sandra A. J. Lawrence | Independent Director | 2021 | 68 |
| Jane F. Barlow | Independent Director | 2022 | 65 |
| Robert H. Getzenberg | Member of Scientific Advisory Board | - | - |
| Amos E. Madanes | Member of Scientific Advisory Board | - | - |
| C. Matthew Peterson | Member of Scientific Advisory Board | - | - |
| D. Ware Branch | Member of Scientific Advisory Board | - | - |
| Robert M. Silver | Member of Scientific Advisory Board | - | - |
| Joshua S. Phillips | Independent Director | 2011 | 59 |
| David G. Grenache | Member of Scientific Advisory Board | - | - |
| Mansoor Raza Mirza | Independent Director | 2014 | 65 |
| Jeffrey T. Elliott | Independent Director | 2025 | 48 |